Evolving Standards of HER2-Positive Breast Cancer
Sunil Verma, MD, MSEd, FRCPC, discusses evolving standards of early stage HER2-positive breast cancer.
Clinical Pearls
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses evolving standards of early stage HER2-positive breast cancer.
- The treatment of HER2-positive breast cancer has come a long way since the discovery that the addition of trastuzumab leads to improvement in disease-free and overall survival.
- Moving forward, the focus should not be just on improving the endpoints of disease-free and overall survival, but also defining the patient population at the highest risk.
- There remains a need to determine how patients can be treated better with less treatment.
<<<
Recent Videos
Related Content
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024Article
During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
